Shouyao Holdings Unveils RMB787 Million Investment in Beijing BioPark R&D and GMP Facility
CompanyDeals

Shouyao Holdings Unveils RMB787 Million Investment in Beijing BioPark R&D and GMP Facility

Biokin's BL-B01D1 Secures NMPA Green-light for Two Phase II Clinical Trials in Gynecological Cancers
CompanyDrug

Biokin’s BL-B01D1 Secures NMPA Green-light for Two Phase II Clinical Trials in Gynecological Cancers

Boehringer Ingelheim Biopharmaceuticals (China) Completes PMDA GMP Inspection for Japan Market Supply
Company

Boehringer Ingelheim Biopharmaceuticals (China) Completes PMDA GMP Inspection for Japan Market Supply

CentryMed's CMDE005 Bispecific Antibody Receives FDA Clinical Approval for EGFR Positive Tumors
CompanyDrug

CentryMed’s CMDE005 Bispecific Antibody Receives FDA Clinical Approval for EGFR Positive Tumors

Pfizer's Inlyta Receives NMPA Approval for First-line Renal Cell Carcinoma Combination Therapy
CompanyDrug

Pfizer’s Inlyta Receives NMPA Approval for First-line Renal Cell Carcinoma Combination Therapy

Anglikang Pharmaceutical Receives NMPA Clinical Clearance for ALK-N001 in Advanced Solid Tumors
CompanyDrug

Anglikang Pharmaceutical Receives NMPA Clinical Clearance for ALK-N001 in Advanced Solid Tumors

Grand Pharma's AcornMed utLIFE-UC Urothelial Carcinoma Assay First Prescription Administered in China
CompanyMedical Device

Grand Pharma’s AcornMed utLIFE-UC Urothelial Carcinoma Assay First Prescription Administered in China

Sihuan Pharmaceutical Wins NMPA Approval for Polylactic Acid Facial Filler
CompanyMedical Device

Sihuan Pharmaceutical Wins NMPA Approval for Polylactic Acid Facial Filler

Roche's Q1 2025 Results: Pharma Sales Drive 8% Growth Amidst Flat Diagnostics
Others

Roche’s Q1 2025 Results: Pharma Sales Drive 8% Growth Amidst Flat Diagnostics

BMS Q1 2025 Results: Opdivo Sales Up 12% Despite Overall Revenue Decline
Company

BMS Q1 2025 Results: Opdivo Sales Up 12% Despite Overall Revenue Decline

Merck & Co. Q1 2025 Results: Keytruda Sales Grow 6% Despite Gardasil Dip in China
Company

Merck Q1 2025 Results: Keytruda Sales Grow 6% Despite Gardasil Dip in China

Hengrui Pharmaceuticals Receives NMPA Clearance for Phase II Trial of SHR-4849, SHR-8068, and Adebrelimab in Advanced Solid Tumors
CompanyDrug

Hengrui Pharmaceuticals Receives NMPA Clearance for Phase II Trial of SHR-4849, SHR-8068, and Adebrelimab in Advanced Solid Tumors